USA-based biopharma firm Silverback Therapeutics (Nasdaq: SBTX) and ARS Pharmaceuticals have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction.
Shares of Silverback traded down more than 10% to $3.94 in after-hours activity yesterday. Earlier this year the company also fell back, when it announced that it is shutting down its targeted oncology programs and cutting its workforce by 27% as it refocuses resources on developing chronic hepatitis B drugs and its ImmunoTAC drug discovery platform. It also reported a net loss of $89.5 million for 2021 compared to a net loss of $32.9 million in 2020.
The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze